Real-world data in patients with congenital hemophilia and inhibitors: final data from the FEIBA Global Outcome (FEIBA GO) study

BACKGROUND: The bypassing agent, activated prothrombin complex concentrate [aPCC, FEIBA (factor VIII inhibitor bypass activity); Baxalta US Inc, a Takeda company, Lexington, MA, USA], is indicated for the treatment of bleeding episodes, perioperative management, and routine prophylaxis in patients w...

Descripción completa

Detalles Bibliográficos
Autores principales: Ettingshausen, Carmen Escuriola, Hermans, Cedric, Holme, Pål A., Cid, Ana R., Khair, Kate, Oldenburg, Johannes, Négrier, Claude, Botha, Jaco, Lelli, Aurelia, Windyga, Jerzy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10387704/
https://www.ncbi.nlm.nih.gov/pubmed/37529276
http://dx.doi.org/10.1177/20406207231184323

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10387704/
https://www.ncbi.nlm.nih.gov/pubmed/37529276
http://dx.doi.org/10.1177/20406207231184323

Ejemplares similares